Lift Biosciences Secures €12M Grant to Advance “First-in-Class” Neutrophil Immunotherapy.
Lift Biosciences has secured a €12 million grant from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its immuno-modulatory alpha neutrophil (IMAN) therapy into first-in-human trials. This marks the largest grant awarded by the DTIF to date and underscores the growing interest in novel immuno-oncology approaches, particularly those targeting solid tumors resistant to current treatments, including checkpoint inhibitors.
This funding infusion raises crucial questions about the evolving landscape of cancer immunotherapy. While T-cell therapies have dominated the field, Lift’s focus on neutrophils—the body’s “first responders”—represents a potential paradigm shift. The company posits that IMANs can overcome the limitations of existing therapies by activating both the innate and adaptive immune systems, leading to a more comprehensive and durable anti-tumor response. This approach, if successful, could address the significant challenge of tumor escape, a primary driver of cancer-related mortality.
The strategic implications of this grant extend beyond scientific validation. Lift’s collaboration with the University of Galway and Hooke Bio underscores a growing trend towards synergistic partnerships within the biotech ecosystem. By combining Lift’s immunotherapy platform with the University of Galway’s clinical trial expertise and Hooke Bio’s advanced analytics, the consortium aims to accelerate clinical development and attract further investment. This model of collaborative innovation could become increasingly crucial as companies seek to navigate the complexities and costs of bringing novel therapies to market.
The trial, slated to begin in Q4 2026, will focus on patients with metastatic cervical or head and neck cancer who have exhausted all standard treatment options. This patient population represents a significant unmet need, highlighting the urgency for innovative therapeutic strategies. The trial’s design, which includes dose escalation and combination therapy with checkpoint inhibitors, will provide valuable data on safety, efficacy, and the potential for IMANs to enhance existing treatment paradigms.
Lift’s progress will be closely monitored by both investors and the broader oncology community. The successful completion of this trial and subsequent attraction of additional funding could validate the potential of neutrophil-based immunotherapies and potentially reshape the future of cancer treatment. Furthermore, the establishment of a clinical and manufacturing program in Galway, Ireland, highlights the increasing globalization of biotech innovation and the potential for emerging hubs to play a critical role in advancing cutting-edge therapies. The question remains: will this approach prove to be a true game-changer in the fight against cancer, or another promising avenue that falls short of its potential?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
